<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1919">
  <stage>Registered</stage>
  <submitdate>9/04/2008</submitdate>
  <approvaldate>9/04/2008</approvaldate>
  <nctid>NCT00658359</nctid>
  <trial_identification>
    <studytitle>Extension Study Of Subjects From Study A3921030 For The Prevention Of Acute Rejection In Kidney Transplant Patients</studytitle>
    <scientifictitle>A Phase 2, Multicenter, Open-label, Active Comparator-controlled, Extension Trial To Evaluate The Long-term Safety And Efficacy Of Cp-690,550 In Renal Allograft Recipients</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>2008-002345-23</secondaryid>
    <secondaryid>A3921050</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Kidney Transplantation</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Cyclosporine
Treatment: drugs - CP-690,550
Treatment: drugs - CP-690,550

Active Comparator: Treatment Arm 1 - Treatment Arm 1 will also receive standard of care medications

Experimental: Treatment Arm 2 - Treatment Arm 2 will also receive standard of care medications

Experimental: Treatment Arm 3 - Treatment Arm 3 will also receive standard of care medications


Treatment: drugs: Cyclosporine
Standard of care

Treatment: drugs: CP-690,550
CP-690,550 tablets dosed BID Months 12-72

Treatment: drugs: CP-690,550
CP-690,550 tablets dosed BID Months 12-72

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Long-term efficacy of CP-690,550</outcome>
      <timepoint>6 years</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Long-term safety and tolerability of CP-690,550</outcome>
      <timepoint>6 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Additional measures of efficacy of CP-690,550</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Effects of CP-690,550 on health outcome assessments</outcome>
      <timepoint>3 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relationship of CP-690,550 concentration and safety/efficacy endpoints</outcome>
      <timepoint>6 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Subjects who successfully completed Study A3921030</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects who are on the waiting list for a second kidney transplant or any non-renal
             organ transplants</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/08/2008</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>178</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/06/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital, Transplant Ambulatory Care - Camperdown</hospital>
    <hospital>Orange Base Hospital - Orange</hospital>
    <hospital>Westmead Hospital, Department of Renal Medicine - Westmead</hospital>
    <hospital>Central Northern Adelaide Renal and Transplantation Service - Adelaide</hospital>
    <hospital>Royal Adelaide Hospital (RAH)- The University of Adelaide - Adelaide</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>The Queen Elizabeth Hospital - Woodville</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2800 - Orange</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5011 - Woodville</postcode>
    <postcode>3050 - Parkville</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Anderlecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>RS</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SP</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Alberta</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czech Republic</country>
      <state>Praha 4</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Ile-de-France</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris Cedex 15</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Vandoeuvre Les Nancy</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>BO</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>RM</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Rotterdam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Oslo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Wroclaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Coimbra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Portugal</country>
      <state>Lisboa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Barcelona</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Pfizer</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a study that will follow transplant patients from Study A3921030 to monitor for long
      term safety, tolerability and efficacy for 5 additional years, except in Portugal where the
      study will follow transplant patients through Month 36 posttransplant. Patients will continue
      their study medications that were previously assigned.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00658359</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Pfizer CT.gov Call Center</name>
      <address>Pfizer</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>